Bladder Cancer

>

Latest News

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.
Cretostimogene Grenadenorepvec Yields Sustained Antitumor Activity in NMIBC

March 25th 2025

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC
UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

March 11th 2025

Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma
Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

March 4th 2025

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.
EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

February 25th 2025

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102
Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

February 15th 2025

More News


Site Logo

Overview of Phase I/II Pemetrexed Studies

November 2nd 2004

Pemetrexed (Alimta) is an antifolate that is effective in the inhibitionof multiple enzyme targets including thymidylate synthase,dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.The compound has been evaluated in several phase I trials, bothas single agent and in combination with other cytotoxic agents. Theinitial schedule selected for further investigation in phase II trials waspemetrexed 600 mg/m2 as a 10-minute infusion on day 1 every 21 days.During the subsequent phase II development, the dose of pemetrexedwas adjusted to 500 mg/m2 due to bone marrow and gastrointestinaltoxicities. The adjusted dose of pemetrexed was well tolerated throughoutthe late-phase drug development program. Preclinical evidencesuggests that pemetrexed has additive or synergistic activity when combinedwith many other clinically important anticancer agents, includinggemcitabine (Gemzar), fluorouracil, carboplatin (Paraplatin),oxaliplatin (Eloxatin), paclitaxel, and vinorelbine (Navelbine). Doselimitingtoxicities in these studies were primarily hematologic, and therewas no evidence of cumulative hematologic toxicity. During the drugdevelopment program it was discovered that supplementation with folicacid and vitamin B12 profoundly increased the tolerability ofpemetrexed. The studies discussed in this review demonstrate thatpemetrexed is well tolerated as a single agent and will be an importantcontribution to combination chemotherapy regimens.